Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.53 -2.8%	$4.51	$2.90 ▼ $11.16	$320.37M	-0.01	2.90 million shs	1.91 million shs
BNTC Benitec Biopharma	$12.70 -1.4%	$12.65	$8.06 ▼ $17.15	$338.11M	0.4	43,661 shs	17,239 shs
EXOZ eXoZymes	$9.31 -4.8%	$10.14	$8.50 ▼ $23.99	$82.07M	N/A	3,258 shs	7,776 shs
RCKT Rocket Pharmaceuticals	$3.73 -0.5%	$2.98	$2.19 ▼ $22.01	$404.64M	0.65	5.21 million shs	9.36 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	-2.75%	-4.08%	-15.95%	-38.18%	-48.62%
BNTC Benitec Biopharma	-1.40%	+0.32%	+12.79%	-3.71%	+41.74%
EXOZ eXoZymes	-4.81%	-6.81%	+1.31%	-37.52%	+930,999,900.00%
RCKT Rocket Pharmaceuticals	-0.53%	+23.10%	+10.68%	-40.51%	-81.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	3.2233 of 5 stars	4.3	3.0	0.0	0.0	1.9	1.7	0.6
BNTC Benitec Biopharma	1.5652 of 5 stars	3.6	1.0	0.0	0.0	2.0	0.8	0.0
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	4.8009 of 5 stars	4.2	4.0	0.0	4.7	1.8	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.57	Moderate Buy	$17.40	392.92% Upside
BNTC Benitec Biopharma	3.13	Buy	$26.00	104.72% Upside
EXOZ eXoZymes	0.00	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	2.41	Hold	$16.73	348.61% Upside

Current Analyst Ratings Breakdown

Latest EXOZ, RCKT, ALT, and BNTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $10.00
8/20/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00
8/13/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/13/2025	ALT Altimmune	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $24.00
8/13/2025	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
8/11/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
8/8/2025	RCKT Rocket Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $8.00
7/25/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
7/25/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$9.00 ➝ $4.00
7/24/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $12.00
7/24/2025	RCKT Rocket Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	15,577.89	N/A	N/A	$1.83 per share	1.93
BNTC Benitec Biopharma	$80K	4,167.19	N/A	N/A	$4.68 per share	2.71
EXOZ eXoZymes	$70K	1,115.87	N/A	N/A	$0.86 per share	10.83
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$3.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.18	N/A	N/A	N/A	-438,730.03%	-62.63%	-55.29%	N/A
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
EXOZ eXoZymes	-$5.86M	N/A	0.00	∞	N/A	N/A	-134.50%	-81.63%	N/A
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.51	N/A	N/A	N/A	N/A	-65.11%	-55.99%	11/6/2025 (Estimated)

Latest EXOZ, RCKT, ALT, and BNTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ALT Altimmune	-$0.32	-$0.27	+$0.05	-$0.27	$0.00 million	$0.01 million
8/12/2025	Q2 2025	EXOZ eXoZymes	N/A	-$0.28	N/A	-$0.28	N/A	N/A
8/7/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	-$0.59	-$0.02	-$0.62	$4.36 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.09	20.44	20.44
BNTC Benitec Biopharma	0.01	14.80	14.80
EXOZ eXoZymes	0.01	6.19	6.19
RCKT Rocket Pharmaceuticals	0.05	6.39	6.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
BNTC Benitec Biopharma	52.19%
EXOZ eXoZymes	N/A
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
BNTC Benitec Biopharma	1.30%
EXOZ eXoZymes	72.41%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	88.26 million	84.64 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
EXOZ eXoZymes	29	8.39 million	2.31 million	N/A
RCKT Rocket Pharmaceuticals	240	107.90 million	81.19 million	Optionable

EXOZ, RCKT, ALT, and BNTC Headlines

Recent News About These Companies

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded to Buy at Bank of America

2 hours ago | americanbankingnews.com

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

August 21 at 12:15 PM | zacks.com

Rocket Pharmaceuticals' (RCKT) "Buy" Rating Reaffirmed at Chardan Capital

August 21 at 3:59 AM | americanbankingnews.com

Rocket Pharmaceuticals announces clinical hold lifted on RP-A501 trial

August 20 at 12:31 AM | msn.com

John Militello Sells 7,043 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock

August 20 at 6:18 PM | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider Sells $33,706.22 in Stock

August 20 at 6:18 PM | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Martin Wilson Sells 12,109 Shares

August 20 at 6:18 PM | marketbeat.com

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

August 20 at 12:03 PM | barrons.com

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

August 20 at 9:31 AM | benzinga.com

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

August 20 at 7:09 AM | reuters.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider John Militello Sells 7,043 Shares

August 19 at 5:01 AM | insidertrades.com

Jefferies Raises PT on Rocket Pharmaceuticals, Inc. (RCKT) to $3.00; Maintains ‘Hold’ Rating

August 19 at 2:30 AM | insidermonkey.com

Rocket Pharmaceuticals Reorganizes, Cuts Workforce by 30% to Focus on AAV Cardiovascular Platform

August 18, 2025 | msn.com

What is Chardan Capital's Forecast for RCKT FY2025 Earnings?

August 16, 2025 | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $16.40 Consensus Price Target from Analysts

August 14, 2025 | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $11.00 at Chardan Capital

August 13, 2025 | americanbankingnews.com

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact Levi & Korsinsky

August 12, 2025 | theglobeandmail.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $11.00 by Analysts at Chardan Capital

August 12, 2025 | marketbeat.com

Rocket Pharmaceuticals Announces Strategic Restructuring and Leadership Changes

August 12, 2025 | theglobeandmail.com

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

August 12, 2025 | theglobeandmail.com

Levi & Korsinsky Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 – RCKT

August 11, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EXOZ, RCKT, ALT, and BNTC Company Descriptions

Altimmune NASDAQ:ALT

$3.53 -0.10 (-2.75%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$3.55 +0.02 (+0.68%)

As of 08/21/2025 07:56 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Benitec Biopharma NASDAQ:BNTC

$12.70 -0.18 (-1.40%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$12.70 0.00 (0.00%)

As of 08/21/2025 05:30 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

eXoZymes NASDAQ:EXOZ

$9.31 -0.47 (-4.81%)

As of 08/21/2025 04:00 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.73 -0.02 (-0.53%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$3.74 +0.02 (+0.40%)

As of 08/21/2025 07:58 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time